Market experts has given a mean price target of $467.86 to Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) stock. The target price is the mean of all calls released by analysts in First Call poll. They have EPS estimate of $2.79 for the near-term quarter and $11.00 for this year.
The technical assessment of Regeneron Pharmaceuticals, Inc. pinpoints that the 50-day moving average of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) stock is $406.28, and is trading $4.11 points away or +1.01% from 50-day moving average of $406.28. It is trading $20.62 or +5.29% off 200-day MA of $389.77.
The 52-week high of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) was $592.59 while $329.09 is the low point in the same period. Regeneron Pharmaceuticals, Inc. share price has to rise more than $-182.20 to register a high for 52-weeks or drop +24.70% to make 52-week low. MA should be referred to as moving average.
Without understanding when a stock is over-valued, or too richly priced, a shareholder may miss out on a chance to cash-in on a profit and investment. Worse, a shareholder might close up their position when a price has no direction.
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) P/E ratio is 64.02 while PEG ratio is at 2.00. By overlooking a firm’s price-to-earnings ratio, a shareholder could miss out to discover the true value of stocks and end up investing in the wrong stocks. A P/E ratio is a computation of how much investors are wanting to pay for a purchasing an equity relative to the firm’s earnings. It is valuable when comparing the equity price of one firm to another trading in the same industry. The P/E ratio is discovered by dividing market value of stock by average earnings per share in a specified period of time, for instance, the past year.
Regeneron Pharmaceuticals, Inc. stock recorded a close of $410.39 in last trading session, which brings it market cap to $42.94B.
1 Chart Pattern Every Investor Should Know
This little-known pattern preceded moves of 578% in ARWR, 562% in LCI, 513% in ICPT, 439% in EGRX, 408% in ADDUS and more...